Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells.
Bone marrow
Clonal mesenchymal stromal cells
GMP
Toxicity
Tumorigenicity
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
26 05 2022
26 05 2022
Historique:
received:
15
12
2021
accepted:
11
05
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
Mesenchymal stromal cells (MSCs) have opened a new window to treat inflammatory and non-inflammatory diseases. Nonetheless, their clinical applications require rigorous control and monitoring procedures to ensure full compliance with the principles of good manufacturing practice (GMP). Various evaluations should be passed in conjunction with the development of these newly emerging therapeutic products from bench-to-bedside. These evaluations include in vitro characterization, preclinical studies, and clinical trials to ensure product safety and efficacy. Therefore, a robust and well-designed preclinical study is critical to confirm product safety. This study aims to determine the probable toxicity effects of local and systemic injections of cryopreserved human bone marrow-derived clonal MSCs (BM-cMSCs) during subacute and subchronic periods of time. BM-cMSCs were characterized according to the International Society for Cell and Gene Therapy (ISCT) criteria for MSCs. Both safety and toxicity of the BM-cMSCs population produced under GMP-compatible conditions were assessed in both sexes of Sprague Dawley (SD) rats via systemic intravenous (IV) administration and local injection in intervertebral disc (IVD). Behavioral changes, clinical signs of toxicity, and changes in body weight, water and food consumption were the important variables for product toxicity testing over 14 consecutive days during the subacute period and 90 consecutive days during the subchronic period. At the end of the assessment periods, the rats were killed for histopathology analysis of the target tissues. The BM-cMSCs potential for tumorigenicity was checked in nude mice. Single IV and IVD injections of BM-cMSCs did not cause significant signs of clinical toxicity, or changes in laboratory and histopathology data during the subacute (14 day) and subchronic (90 day) periods. Ex vivo-expanded and cryopreserved BM-cMSCs did not induce tumor formation in nude mice. The results suggest that local and systemic administrations of xenogeneic BM-cMSCs in both sexes of SD rats do not cause toxicity during the subacute and subchronic periods of time. Also, BM-cMSCs were non-tumorigenic in nude mice.
Identifiants
pubmed: 35619148
doi: 10.1186/s13287-022-02899-9
pii: 10.1186/s13287-022-02899-9
pmc: PMC9137136
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
213Informations de copyright
© 2022. The Author(s).
Références
Cell Stem Cell. 2014 Feb 6;14(2):141-5
pubmed: 24506881
Stem Cell Rev Rep. 2022 Feb 17;:
pubmed: 35175538
J Clin Diagn Res. 2017 Sep;11(9):FF01-FF03
pubmed: 29207730
Tissue Eng Part A. 2014 Oct;20(19-20):2549-54
pubmed: 24749762
Front Immunol. 2014 May 19;5:148
pubmed: 24904568
Stem Cell Res Ther. 2017 Nov 15;8(1):262
pubmed: 29141662
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Tissue Eng Part C Methods. 2015 Dec;21(12):1251-62
pubmed: 26421757
Stem Cell Res Ther. 2012 Sep 28;3(5):38
pubmed: 23021082
Inflamm Regen. 2017 Jul 3;37:16
pubmed: 29259715
Tissue Eng Part B Rev. 2010 Aug;16(4):445-53
pubmed: 20196648
Front Immunol. 2012 Aug 14;3:253
pubmed: 22912639
Indian J Med Res. 2016 Dec;144(6):852-864
pubmed: 28474622
Korean J Physiol Pharmacol. 2016 Jan;20(1):63-7
pubmed: 26807024
Spine J. 2021 Feb;21(2):212-230
pubmed: 33045417
J Korean Med Sci. 2011 Apr;26(4):482-91
pubmed: 21468254
Cell Mol Biol Lett. 2021 Jan 20;26(1):3
pubmed: 33472580
Fed Regist. 2008 Jul 15;73(136):40453-63
pubmed: 18850678
Stem Cells Transl Med. 2012 Dec;1(12):909-20
pubmed: 23283552
Ann Rheum Dis. 2017 Jan;76(1):196-202
pubmed: 27269294
Rheumatology (Oxford). 2006 Oct;45(10):1187-93
pubmed: 16777856
Stem Cells Dev. 2014 May 15;23(10):1074-83
pubmed: 24417334
Spine (Phila Pa 1976). 2007 Feb 1;32(3):328-33
pubmed: 17268264
Stem Cells Int. 2014;2014:292109
pubmed: 24738002
J Tissue Eng Regen Med. 2018 Feb;12(2):e1034-e1045
pubmed: 28112873
Stem Cells. 2019 Jul;37(7):855-864
pubmed: 30977255
Stem Cells Int. 2013;2013:732742
pubmed: 24000286
Stem Cell Res Ther. 2019 Jun 25;10(1):187
pubmed: 31238982
Cell Death Dis. 2021 Jun 2;12(6):566
pubmed: 34075029
Stroke. 2019 Nov;50(11):3299-3306
pubmed: 31658004
Materials (Basel). 2018 Aug 03;11(8):
pubmed: 30081464
J Clin Med. 2021 Jun 29;10(13):
pubmed: 34210026
J Cereb Blood Flow Metab. 2014 Jan;34(1):e1-9
pubmed: 24169850
Stem Cells Int. 2013;2013:496218
pubmed: 23577036
Stem Cells Cloning. 2011 Nov 17;4:61-72
pubmed: 24198531
Nat Biotechnol. 2014 Aug;32(8):721-3
pubmed: 25093890
Cell Transplant. 2006;15(8-9):711-21
pubmed: 17269442
J Transl Med. 2011 Oct 21;9:181
pubmed: 22017805
Cytotherapy. 2019 May;21(5):546-560
pubmed: 30878384
Cells. 2020 Jul 10;9(7):
pubmed: 32664207
PLoS One. 2017 Apr 27;12(4):e0175449
pubmed: 28448518
Eur J Pharmacol. 2015 Jul 15;759:51-62
pubmed: 25814257
Oral Oncol. 2013 Feb;49(2):136-43
pubmed: 22981389
Stem Cells Dev. 2008 Jun;17(3):451-61
pubmed: 18513161
Stem Cells Dev. 2011 Aug;20(8):1297-308
pubmed: 21303266
Stem Cells Dev. 2009 Jun;18(5):683-92
pubmed: 19099374